Drugs / Ruxolotinib
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT01795677 | Dec 2012 → May 2018 | myelofibrosis | French Innovative Leukemia Organisation | Completed | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Ruxolotinib | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01795677 ↗ |
| Known as | RUXOLITINIB | “JAK2 inhibitor RUXOLITINIB” NCT01795677 ↗ |
| Action | Inhibit | “JAK2 inhibitor RUXOLITINIB” NCT01795677 ↗ |
| Target | JAK2 | “JAK2 inhibitor RUXOLITINIB” NCT01795677 ↗ |